Radiation plus immunotherapy for large relapsed solid tumors
Part of Cancer clinical trials.
This trial tests a new combination of radiation therapy and two immunotherapy drugs (Iparomlimab and Tuvonralimab) for people whose solid tumors have returned or spread and are too large for standard surgery. The goal is to shrink the tumor and control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have a solid tumor that has come back or spread, and it is at least 6 cm wide (about the size of a lemon) but cannot be removed with standard surgery.
- You are generally able to take care of yourself (ECOG score 0-2).
- Your major organs (kidneys, liver, blood cells) are working well enough, as shown by recent blood tests.
- You have not had other cancer treatments (like chemotherapy or radiation) in the last 4 weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests two immunotherapy medicines (iparomlimab and tuvonralimab) combined with radiation and standard chemotherapy for advanced head and neck cancer that cannot be removed with surgery. The goal is to see if adding these medicines helps shrink tumors and improve outcomes.
This trial tests a combination of low-dose radiation, focused high-dose radiation, and an immunotherapy drug (tislelizumab) for people with large, advanced solid tumors that have not responded to standard treatments.
This trial tests whether adding targeted radiation to your metastatic tumors can help your immunotherapy work better. It is for people with advanced solid tumors that have spread to 3-10 spots and who have been on immunotherapy for at least 3 months.
This trial tests combining two types of radiation therapy with an immunotherapy drug for people with advanced solid tumors that have spread or come back. The goal is to see if this approach can help when standard treatments have stopped working or aren’t an option.
This study is tracking how well a combination of two immunotherapy medicines (iparomlimab and tuvonralimab) works in people with advanced cancers. It's a real-world study, meaning you get the treatment as part of your regular care, and the researchers observe the results.
This trial tests a new type of radiation combined with immunotherapy for people with advanced solid tumors that are no longer responding to standard treatments or cannot tolerate them. The goal is to see if this combination can help control the disease.
Hear when a new Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.